

The Eular Journal

Impact Factor: 16.102



Editor

Josef S Smolen

Associate Editors

Francis Berenbaum **Dimitrios Boumpas** Gerd Burmester Mary Crow Kimme Hyrich Rik Lories lain McInnes Thomas Pap David Pisetsky Désirée van der Heijde Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases BMJ Publishing Group Ltd RMA House Tavistock Square London WCIH 9JR,UK T: +44 (0)20 3655 5889 E: ard@bmi.com

Twitter: @ARD_BMJ ISSN: 0003-4967 (print) ISSN: 1468-2060 (online)

Disclaimer: The Editor of ARD has been granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither EULAR nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from ARD (except for liability which cannot be legally excluded).

Copyright: © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc. 150-15, 183rd Street, Jamaica, NY 11413, USA, Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Contents

Editorial

137 Glucocorticoids: surprising new findings on their mechanisms of actions F Buttgereit

Heroes and pillars of rheumatology

140 Johann Lucas Schoenlein (1793–1864): impact without publications

B Manger, G Schett, G R Burmester

Review



143 Mechanisms of progressive fibrosis in 6 connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

> P Spagnolo, O Distler, C J Ryerson, A Tzouvelekis, J S Lee, F Bonella, D Bouros, A-M Hoffmann-Vold, B Crestani, E L Matteson

Viewpoint

151 Tackling osteoarthritis during COVID-19 pandemic

F A Castro da Rocha, L d P Melo, F Berenbaum

Rheumatoid arthritis

154 Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a nonclinical setting

> E A Bemis, M K Demoruelle, I A Seifert, K J Polinski, M H Weisman, J H Buckner, PK Gregersen, TR Mikuls, IR ODell, R M Keating, K D Deane, V M Holers, I M Norris

162 Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis

> Z Cheng, T Do, K Mankia, I Meade, L Hunt, V Clerehugh, A Speirs, A Tugnait, P Emery, D Devine

169

Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden

Volume 80 Issue 2 | ARD February 2021

V Molander, H Bower, T Frisell, J Askling

In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells

> B Zhang, Y Wang, Y Yuan, J Sun, L Liu, D Huang, J Hu, M Wang, S Li, W Song, H Chen, D Zhou, X Zhang

Psoriatic arthritis

185 Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

> P J Mease, P S Helliwell, K F Hjuler, K Raymond, I McInnes

Paediatric rheumatology

194 Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibodyexposed newborns at risk of congenital heart block

> M Ivanchenko, G E Thorlacius, M Hedlund, V Ottosson, L Meneghel, S Björkander, A Ossoinak, J Tingström, K Bremme, E Sverremark-Ekström, K Gemzell-Danielsson, S-E Sonesson, K Chemin, M Wahren-Herlenius

Systemic lupus erythematosus

203 Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial

> C Aranow, Y Atish-Fregoso, M Lesser, M Mackay, E Anderson, S Chavan, T P Zanos, T Datta-Chaudhuri, C Bouton, K J Tracey, B Diamond

MORE CONTENTS ▶



OPEN ACCESS

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See http://authors.bmj.com/open-access/



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

http://publicationethics.org/



Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus

> K R Bashant, A M Aponte, D Randazzo, P Rezvan Sangsari, A IT Wood, I A Bibby, E E West, A Vassallo, Z G Manna, M P Playford, N Iordan, S Hasni, M Gucek, C Kemper, A Conway Morris, NY Morgan, N Toepfner, I Guck, N N Mehta, E R Chilvers, C Summers, M J Kaplan

Systemic sclerosis

219

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

A-M Hoffmann-Vold, Y Allanore, M Alves, C Brunborg, P Airó, L P Ananieva, L Czirják, S Guiducci, E Hachulla, M Li, C Mihai, G Riemekasten, P P Sfikakis, O Kowal-Bielecka, A Riccardi, O Distler, on behalf of EUSTAR collaborators

228 Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement

> K Showalter, R Spiera, C Magro, P Agius, V Martyanov, J M Franks, R Sharma, H Geiger, TA Wood, Y Zhang, CR Hale, J Finik, M L Whitfield, D E Orange, J K Gordon

Epidemiology

238 Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort

> A Ciurea, E Papagiannoulis, K Bürki, I von Loga, R Micheroli, B Möller, A Rubbert-Roth, M Andor, R Bräm, A Müller, D Dan, D Kyburz, O Distler, A Scherer, A Finckh

242 Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group

> S M Nielsen, M Uggen Rasmussen, M Boers, D A van der Windt, M de Wit, T G Woodworth, C A Flurey, D Beaton, B Shea, R Escorpizo, D E Furst, J S Smolen, K Toupin-April, A Boonen, M Voshaar, T Ellingsen, G A Wells, B C Reeves, L March, P Tugwell, R Christensen

Therapy



250 Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids

> C Fenton, C Martin, R Jones, A Croft, J Campos, A J Naylor, A E Taylor, M Chimen, M Cooper, G G Lavery, K Raza, R S Hardy

Imaging

261 Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study

> G Filippou, A Scanu, A Adinolfi, C Toscano, D Gambera, R Largo, E Naredo, E Calvo, G Herrero-Beaumont, P Zufferey, C M Bonjour, D K MacCarter, S Makman, Z Weber, F Figus, I Möller, M Gutierrez, C Pineda, D Clavijo Cornejo, H Garcia, V Ilizaliturri, J Mendoza Torres, R Pichardo, L C Rodriguez Delgado, E Filippucci, E Cipolletta, T Serban, C Cirstoiu, F A Vreju, D Grecu, G Mouterde, M Govoni, L Punzi, N S Damjanov, H I Keen, G AW Bruyn, L Terslev, M-A D'Agostino, C A Scirè, A Iagnocco

Letters

269 SARS CoV-2 infection among patients using immunomodulatory therapies

K L Winthrop, A E Brunton, S Beekmann, P Polgreen, J Baddley, K G Saag, C Calabrese, L Calabrese, P C Robinson, Z S Wallace, J R Curtis, the COVID-19 Study Team

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a casecontrol study

> N Potere, M Di Nisio, D Cibelli, R Scurti, A Frattari, E Porreca, A Abbate, G Parruti

Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics A Mendel, S Bernatsky, A Askanase, S-C Bae, A E Clarke, N Costedoat-Chalumeau, D D Gladman, C Gordon, J Hanly, S Jacobsen, K Kalunian, A Mak, M Mosca, B A Pons-Estel, G Ruiz-Irastorza, M Urowitz, É Vinet

274 The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series

> N Serling-Boyd, A M Mohareb, A Y Kim, E P Hyle, Z S Wallace

Electronic pages

- e12 Coronavirus disease 19 (Covid-19) and nonsteroidal anti-inflammatory drugs (NSAID) A Giollo, G Adami, D Gatti, L Idolazzi, M Rossini
- Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and nonsteroidal anti-inflammatory drugs (NSAID)' by Giollo et al S Monti, C Montecucco

e14 COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs

E Conticini, E Bargagli, M Bardelli, G D Rana, C Baldi, P Cameli, S Gentileschi, D Bennett, P Falsetti, N Lanzarone, F Bellisai, C Barreca, R D'Alessandro, L Cantarini, B Frediani

- Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al S Monti, C Montecucco
- e16 Rheumatic diseases in intensive care unit patients with COVID-19 S Moiseev, S Avdeev, M Brovko, A Yavorovskiy,

P I Novikov, K Umbetova, L Akulkina, Nya Tsareva, V Fomin

- e17 Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al S Monti, C Montecucco
- **e18** What is the true incidence of COVID-19 in patients with rheumatic diseases? *E G Favalli, F Ingegnoli, R Cimaz, R Caporali*
- e19 Is there a future for hydroxychloroquine/ chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?

S Moiseev, S Avdeev, M Brovko, P Novikov, V Fomin

e20 Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.

F R Spinelli, F Ceccarelli, M Di Franco, F Conti

e21 Patients with lupus are not protected from COVID-19

A H Sawalha

e22 No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit

V C Romão, A R Cruz-Machado, J E Fonseca

- e23 SLE patients are not immune to covid-19: importance of sending the right message across

 M Goyal
- Patients with lupus are not protected from COVID-19: a comment' by Sawalha, 'No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit' by Romão et al and 'SLE patients are not immune to COVID-19: importance of sending the right message across' by Goyal

B Joob, V Wiwanitkit

e25 Are patients with systemic lupus erythematosus at increased risk for COVID-19?

E G Favalli, M Gerosa, A Murgo, R Caporali

- e26 Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli et al A Mathian, Z Amoura
- e27 Correction: Knee osteoarthritis risk in non-industrial societies undergoing an energy balance transition: evidence from the indigenous Tarahumara of Mexico
- **e28** Correction: High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics